FDA Approves Corcept's Lifyorli for Platinum-Resistant Ovarian Cancer Months Early on March 26, 2026 130-nm albumin-bound paclitaxel Approved Corcept Therapeutics Lifyorli ovarian neoplasm relacorilant ROSELLA trial United States Food and Drug Administration +
FDA Rejects Relacorilant for Cushing's Syndrome High Blood Pressure on January 02, 2026 Corcept Therapeutics' Cushing 's syndrome Hypertensive disease rejection relacorilant United States Food and Drug Administration +